Benchmark Capital Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Benchmark Capital Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	$533K	Sell	34,544 -7,000	-17%	-$144K	0.53%	53
2018 Q3	$895K	Sell	41,544 -2,700	-6%	-$62.7K	0.67%	49
2018 Q2	$1.08M	Sell	44,244 -800	-2%	-$16.3K	0.81%	42
2018 Q1	$770K	Sell	45,044 -2,500	-5%	-$48.8K	0.61%	52
2017 Q4	$901K	Buy	47,544 +17,700	+59%	+$266K	0.7%	44
2017 Q3	$525K	Sell	29,844 -2,100	-7%	-$47.3K	0.41%	67
2017 Q2	$1.06M	Sell	31,944 -300	-0.9%	-$9.29K	0.84%	42
2017 Q1	$1.03M	Buy	32,244 +1,600	+5%	+$54.6K	0.82%	39
2016 Q4	$1.11M	Buy	30,644 +15,175	+98%	+$606K	0.92%	34
2016 Q3	$712K	Hold	15,469	–	–	0.54%	53
2016 Q2	$777K	Buy	15,469 +1,494	+11%	+$79.5K	0.63%	49
2016 Q1	$748K	Buy	+13,975	New	+$820K	0.66%	48

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return

Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Benchmark Capital Advisors's TEVA Position: Q4 2018 in Review

Benchmark Capital Advisors reduced its Teva Pharmaceuticals (TEVA) stake by 17% in Q4 2018, selling an estimated $144K and leaving 34,544 shares worth $533K. The position accounts for 0.53% of the portfolio, ranked #53.

Benchmark Capital Advisors first reported a position in TEVA in Q1 2016 and has held it in 12 quarters since. The position peaked at $1.11M in Q4 2016. 552 funds tracked by Wall St. Rank hold TEVA as of Q4 2018.

Benchmark Capital Advisors held 34,544 shares of Teva Pharmaceuticals worth $533K as of Q4 2018.
Benchmark Capital Advisors sold 7,000 Teva Pharmaceuticals shares in Q4 2018, an estimated $144K.
Teva Pharmaceuticals made up 0.53% of Benchmark Capital Advisors's portfolio in Q4 2018, its #53 holding.
Benchmark Capital Advisors first reported a position in Teva Pharmaceuticals in Q1 2016 and has held it in 12 quarters since.
Benchmark Capital Advisors's Teva Pharmaceuticals position peaked at $1.11M in Q4 2016.
552 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2018.

Based on Benchmark Capital Advisors's 13F filing for Q4 2018, filed 11 Feb 2019.